Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by D'Antonio, D.
Right arrow Articles by Favalli, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D'Antonio, D.
Right arrow Articles by Favalli, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1994) 33, 837-844
© 1994 The British Society for Antimicrobial Chemotherapy


other

Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies

D. D'Antonioa,*, R. Piccolominib, A. Iaconea, G. Fioritonia, G. Parrutic, S. Bettia, A. M. Quagliettaa, P. Accorsia, M. Dell'Isolaa and C. Favallid

aDepartment of Haematology-Microbiology Laboratory, Pescara Civil Hospital Chieti, Italy bDepartment of Microbiology, Institute of Experimental Medicine, ‘G.D'Annunzio’ University Chieti, Italy cConsorzio Mario Negri Sud, Institute of Pharmacological Research ‘Mario Negri’, S. Maria Imbaro Chieti, Italy dDepartment of Experimental Medicine and Biochemical Sciences, Tor Vergata University—IRCCS.—S. Lucia Rome, Italy

Received 1 February 1993; accepted 26 October 1993


The efficacy of oral prophylaxis with ciprofloxacin, ofloxacin or pefloxacin was assessed in preventing bacterial infection in neutropenic patients with treatment being allocated randomly before beginning chemotherapy. Bacteraemia developed in six of 78 episodes (8%) treated with ciprofloxacin, in eight of 80 (10%) allocated to ofloxacin and in 12 of 77 (16%) when pefloxacin was given. However, there were no episodes involving Gram-negative bacilli among those given ciprofloxacin whereas three and seven episodes occurred in patients given ofloxacin or pefloxacin respectively (P = 0•013). With the exception of Pseudomonas aeruginosa, all potential pathogens isolated were resistant to all three fluoroquinolones. Faecal anaerobes were not affected by treatment with pefloxacin whereas their total numbers were reduced in 12 cases who had received ofloxacin and in nine cases who had been given ciprofloxacin (P = 0•002). Fourteen patients (18%) were colonized with pefloxacin resistant P. aeruginosa at the end of treatment with this agent compared with only two and five of those given ciprofloxacin or ofloxacin respectively. A similar trend was seen with other resistant Gram-negative bacilli colonizing 14%, 20% and 23% of patients for ciprofloxacin, ofloxacin and pefloxacin, respectively. Ciprofloxacin was therefore superior to the other two fluoroquinolones in preventing infections due to Gram-negative bacteria in this population of neutropenic patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
A. Gafter-Gvili, M. Paul, A. Fraser, and L. Leibovici
Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis
J. Antimicrob. Chemother., January 1, 2007; 59(1): 5 - 22.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
A. Gafter-Gvili, A. Fraser, M. Paul, and L. Leibovici
Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients
Ann Intern Med, June 21, 2005; 142(12_Part_1): 979 - 995.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.